Reuters logo
BRIEF-Agile Therapeutics to resubmit Twirla NDA to FDA by Q2 2017-end
April 27, 2017 / 12:28 PM / 7 months ago

BRIEF-Agile Therapeutics to resubmit Twirla NDA to FDA by Q2 2017-end

April 27 (Reuters) - Agile Therapeutics Inc:

* Plans to resubmit its New Drug Application for Twirla to U.S. Food and Drug Administration by end of Q2 of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below